Successful use of rituximab in the treatment of childhood and juvenile pemphigus

Vinay, Keshavamurthy; Kanwar, Amrinder J.; Sawatkar, Gitesh U.; Dogra, Sunil; Ishii, Norito; Hashimoto, Takashi

doi:10.1016/j.jaad.2014.05.071

Cited by 46 publications

(47 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was administered as per the “body-weight regimen” (375 mg/m 2 body surface area, twice, 15 days apart) as described by Vinay et al . [9] Although no serious infection was documented in our patients, Kong et al . noted the development of neutropenic sepsis in their PV patient treated with rituximab,[5] highlighting the importance of clinical vigilance for serious infections.…”

Section: Discussioncontrasting

confidence: 50%

“…[58] As it is the case with pemphigus in adult age, rituximab represents a valuable treatment option for pediatric patients, as well. [9] In both of our patients, rituximab was required to obtain remission. It was administered as per the “body-weight regimen” (375 mg/m 2 body surface area, twice, 15 days apart) as described by Vinay et al .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Autoimmune bullous disease in childhood

2017

View full text Add to dashboard Cite

Background:Autoimmune bullous disorders (AIBDs) are a heterogeneous group of diseases which are rarely seen in children. Studies concerning the immunobullous diseases in pediatric patients are scarce.Aims and Objectives:In this study, we aimed to investigate the clinical features and treatment outcomes of AIBDs in children.Materials and Methods:The electronic records of the patients in our AIBDs outpatient clinic were retrospectively reviewed. All cases diagnosed before the age of 16 years were included in the analysis of clinical features, treatment outcomes, and follow-up data.Results:Of the 196 patients with immunobullous diseases, 9 (4.6%) were diagnosed before the age of 16 years. Mean age of the patients at the time of diagnosis was 7.72 ± 5.66 years. Among nine patients, linear immunoglobulin A disease (LAD), pemphigus vulgaris (PV), and bullous pemphigoid (BP) were seen in 5, 2, and 2 children, respectively. All patients were treated with at least two systemic agents (including methylprednisolone, dapsone, methotrexate, salazopyrine, intravenous Ig [IVIg], and rituximab) leading to clinical remission in all of them after a mean period of 31.77 ± 27.99 months.Conclusion:In line with earlier studies, LAD was the most common immunobullous disease and in general, associated with a favorable response to dapsone. This study was noteworthy in that the patients with PV and BP demonstrated a relatively more recalcitrant course, requiring rituximab and IVIg for remission, respectively. Overall, patients had a good prognosis.

show abstract

Section: Discussioncontrasting

confidence: 50%

Section: Discussionmentioning

confidence: 99%

Autoimmune bullous disease in childhood

2017

View full text Add to dashboard Cite

show abstract

“…Rituximab is a monoclonal antibody directed against the CD20 antigen on B cell‐lymphocytes. It has been showed efficacy and safety in several autoimmune pediatric diseases such as hemolytic anemia, chronic idiopathic thrombocytopenic purpura, systemic lupus erythematosus, pemphigus vulgaris, and bullous pemphigoid . However, its use in pediatric patients with MMP has not been reported.…”

mentioning

confidence: 99%

“…A specific protocol for the use of rituximab to treat childhood MMP is not yet available. We used rituximab 375 mg/m 2 at 2‐week intervals as was successfully used by Vinay et al in pediatric patients with pemphigus vulgaris . We believe that rituximab therapy may be considered earlier on the disease course for childhood MMP refractory to classical immunosuppressive therapy to avoid serious and irreversible complications.…”

mentioning

confidence: 99%

Childhood ocular mucous membrane pemphigoid successfully treated with rituximab

Flores-Climente

Rozas‐Muñoz

Martínez-Grau

et al. 2019

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…[30,31] We have used rituximab in 10 patients of childhood and juvenile pemphigus with a complete remission rate of 80%. [32] Though early reports are encouraging, more data is required on the long term safety of rituximab in childhood pemphigus.…”

mentioning

confidence: 99%